US 2024/0174749 A1 · METHODS OF TREATING CANCER WITH ANTIBODIES AGAINST TIM3

Methods of treating cancer with antibodies against tim3

AssigneeBristol-Myers Squibb Company

InventorsXiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING

Life of this patent

Estimating the term…

Abstract

This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.

Claims32

Dependent claims

A method of treating a subject afflicted with a tumor comprising administering to the subject a therapeutically effective amount of an antibody that binds specifically to a human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) and, inhibits TIM3 activity (“anti-TIM3 antibody”), wherein the anti-TIM3 antibody is administered at a flat dose ranging from about 4 mg to about 960 mg or a weight-based dose ranging from about 0.05 mg/kg to about 12 mg/kg.

Dependencies are inferred from the claim text.